What side effects are associated with this type of intervention?

High-power prism glasses, used for field of view expansion in patients with homonymous hemianopia, are generally well-tolerated but can have some side effects. Common issues may include visual distortions, such as image jump or double vision, and initial discomfort or difficulty in adapting to the prisms. Some patients might experience headaches or eye strain as they adjust to the new visual input. It is important for patients to work closely with their eye care provider to ensure proper fitting and to address any adaptation challenges.

What prior FDA approvals exist?

There are no specific FDA-approved treatments for Homonymous Hemianopia mentioned in the provided context. The clinical trial referenced is evaluating high-power prism glasses designed to expand the field of view for patients with this condition. These glasses aim to improve visual function by redirecting images from the non-seeing area to the seeing area of the visual field. Other treatments for visual field loss may include vision therapy and compensatory strategies, but specific FDA-approved drugs or devices for Homonymous Hemianopia are not detailed in the provided information.

What other types of research exist?

Promising novel alternatives to High-Power Prism Glasses for Homonymous Hemianopia patients in 2024 include: 1) Augmented Reality (AR) glasses that use digital overlays to enhance the visual field, 2) Virtual Reality (VR) training programs designed to improve visual processing and neuroplasticity, and 3) Advanced neurostimulation techniques that aim to restore visual field function through brain stimulation. These alternatives are currently being explored in clinical settings and show potential for improving the quality of life for patients with Homonymous Hemianopia.

← Back to Search

Optical Device

Prism Glasses for Hemianopia

N/A

Waitlist Available

Led By Eli Peli, OD MSc

Research Sponsored by Massachusetts Eye and Ear Infirmary

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Homonymous hemianopia with or without macular sparing for at least 6 months

Able to walk independently, using a cane or walker if needed

Must not have

Central visual field loss in the seeing hemifield of either eye (e.g. from macular degeneration, glaucoma, diabetic retinopathy or other maculopathies)

Significant cognitive impairment

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at 6 months

Awards & highlights

No Placebo-Only Group

Summary

This trial tests special glasses with powerful lenses to help people who have lost half of their vision on the same side in both eyes. The glasses work by bending light to expand their field of vision, making it easier to detect obstacles.

Who is the study for?

This trial is for individuals with homonymous hemianopia, which means they've lost half of their field of vision in both eyes. Participants must have at least 20/50 vision with correction, a refractive error within -12D to +5D, and be able to walk independently. They should not have conditions like dementia or significant cognitive impairment that would affect mobility or the use of prism glasses.

What is being tested?

The study is testing two types of prism glasses designed to expand the field of view: Multi-Periscopic Prism (MPP) glasses and Fresnel Peripheral Prism (FPP) glasses. The effectiveness of these glasses will be compared in helping patients navigate their environment.

What are the potential side effects?

Potential side effects may include discomfort adjusting to new visual perspectives, possible eye strain or headaches as users adapt to the prisms, and potential challenges with depth perception.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have had partial vision loss in both eyes for at least 6 months.

Select...

I can walk on my own, even if I need a cane or walker.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have vision loss in part of my field of view due to an eye condition.

Select...

I have significant difficulties with my memory or thinking.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at 6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and at 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in detection rate for hazards approaching from the blind side in the VR walking simulator test

Secondary study objectives

Change in detection response time for hazards approaching from the blind side in the VR walking simulator test

Continuation rate (at end of crossover)

Continuation rate (long term)

+1 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Group I: MPP first, FPP secondExperimental Treatment2 Interventions

Participants in this arm will receive the MPP in the first period of the crossover and the FPP in the second period.

Group II: FPP first, MPP secondExperimental Treatment2 Interventions

Participants in this arm will receive the FPP in the first period of the crossover and the MPP in the second period.

0 / 4Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

High-power prism glasses work by shifting images from the non-seeing side of the visual field to the seeing side, effectively expanding the field of view for patients with homonymous hemianopia. This is crucial for these patients as it helps them to better navigate their environment, avoid obstacles, and improve their overall quality of life. By redirecting light to the functional part of the retina, these glasses can significantly reduce the visual impairment caused by the loss of half the visual field in both eyes.

[Effect of infrared low-intensity laser therapy on orbital blood circulation in children with progressive short sightedness].